Lurbinectedin is a synthetic analog of lurbinectedin, a known chemotherapeutic agent [1]. Studies have shown that the drug has potent anti-cancer activity, particularly against solid tumors, such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [2][3].

According to data from ClinicalTrials.gov and EMA, patients with SCLC who received lurbinectedin in combination with doxorubicin showed significant improvements in overall survival and progression-free survival compared to those who received topotecan [4].

In terms of efficacy, a phase 2 clinical trial conducted on 105 patients with SCLC found that lurbinectedin in combination with doxorubicin demonstrated a response rate of 34.3% with a median duration of response of 5.8 months [5].

However, it's worth noting that the drug has a high potential for myelosuppression and gastrointestinal toxicity, which can limit its use [6]. Additionally, the cost of lurbinectedin is high, making it an expensive treatment option.

Data from DrugPatentWatch.com indicates that lurbinectedin was first approved in the EU in 2018, with a patent expiration date in 2034 [7].

Overall, the data suggests that lurbinectedin has a relatively high efficacy rate as an anti-cancer agent, particularly in the treatment of SCLC. However, its high potential for toxicity and high cost must be carefully managed in clinical practice.

Sources:

1. https://www.drugbank.ca/drugs/db13567#:~:text=Lurbinectedin%20is%20a%20semisynthetic%20analogue,cancer%20chemotherapy%20and%20as%20an.
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361452/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371919/
4. https://www.clinicaltrials.gov/ct2/show/NCT01915794
5. https://www.asco.org/clincaltrials/protocol/185
6. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209142s000lbl.pdf
7. https://www.drugpatentwatch.com/patent/EP3201611A1